Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.

The Prostate - 15 May 2007

Priulla Marcella, Calastretti Angela, Bruno Paola, Azzariti Amalia, Amalia Azzariti, Paradiso Angelo, Canti Gianfranco, Nicolin Angelo

Abstract excerpt

BACKGROUND: In prostate cancer, mutations of the phosphatase PTEN can activate the kinase cascade PI3K/Akt/mTOR which induces drug resistance. METHODS: Chemosensitization by siRNA targeting Akt was studied in HEK293 cells forced to express CA-Akt or kinase-dead DN-Akt. To decrease drug resistance, Akt was silenced with siRNA in human prostate DU-145 cell line expressing the normal PTEN or in LNCaP and PC3 cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Gene Silencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Protein v-akt

Share to Paclitaxel

Share to Prostate

Share to PTEN Phosphohydrolase

Share to RNA, Small Interfering

Share to Tubulin Modulators

Source

Identifiers

PMID: 17373720
DOI: 10.1002/pros.20566

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.PMID 17373720Read ↗

Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.Semantic proximity Read ↗

Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).Semantic proximity Read ↗

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Semantic proximity Read ↗

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitroSemantic proximity Read ↗

Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.Semantic proximity Read ↗

PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A.Semantic proximity Read ↗

Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.Semantic proximity Read ↗

Vulnerabilities of <i>PTEN</i> – <i>TP53</i> -Deficient Prostate Cancers to Compound PARP–PI3K InhibitionSemantic proximity Read ↗

PTEN Mutations Trigger Resistance to ImmunotherapySemantic proximity Read ↗

Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.Semantic proximity Read ↗

PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapySemantic proximity Read ↗

PTEN Mutant Non-Small Cell Lung Cancer Require ATM to Suppress Pro-Apoptotic Signalling and Evade RadiotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.